CLK-IN-T3 NEW
| Price | $50 | $120 | $207 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-11-10 |
Product Details
| Product Name: CLK-IN-T3 | CAS No.: 2109805-56-1 |
| Purity: 99.61% | Supply Ability: 10g |
| Release date: 2025/11/10 |
Product Introduction
Bioactivity
| Name | CLK-IN-T3 |
| Description | CLK-IN-T3 is an inhibitor of CLK1, CLK2, and CLK3 with IC50s of 0.67, 15, and 110 nM. CLK-IN-T3 exhibits anti-cancer activity. |
| In vitro | CLK-IN-T3 (0.5, 1.0 μM) decreases the phosphorylation of CLK-targeted SR proteins and CLK proteins increase slightly. CLK-IN-T3 (0.1, 0.5, 1.0, 5.0, 10.0 µM) results in mild cell cycle arrest at the G2/M boundary with a long-duration of 24 h. CLK-IN-T3 inhibits DYRK1A and DYRK1B with IC50s of 260 and 230 nM[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 4.5 mg/mL (9.32 mM), Sonication and heating are recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.07 mM), Sonication is recommended. |
| Keywords | stable | kinase | Inhibitor | inhibit | DYRK1B | DYRK1A | DYRK | Dual specificity tyrosine regulated kinase | Dual specificity tyrosine phosphorylation regulated kinase | Cyclin dependent kinase | CLK-IN-T-3 | CLK-IN-T3 | CLKINT3 | CLK3 | CLK2 | CLK1 | CLK IN T3 | CLK | CDK | CDC-like | anti-cancer | activity |
| Inhibitors Related | Ribociclib | Harmine | Ro-3306 | Abemaciclib | Rafoxanide | Palbociclib monohydrochloride | CASIN | Palbociclib | GW 441756 | Sodium Oxamate | Dinaciclib | Abemaciclib methanesulfonate |
| Related Compound Libraries | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1Box |
VIP1Y
|
Shanghai Yimeixin Technology Co., LTD
|
2025-09-26 | |
| $5.00/1Box |
VIP1Y
|
Hebei Jiafan Trading Company Limited
|
2025-01-08 | |
| $0.00/1klg |
VIP2Y
|
Shaanxi Xianhe Biotech Co., Ltd
|
2025-04-15 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY